We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients.
- Authors
Waalboer-Spuij, Rick; Holterhues, Cynthia; van Hattem, Simone; Schuttelaar, Marie Louise A; Gaastra, Menno T W; Kuijpers, Daniëlle I M; Hollestein, Loes M; Nijsten, Tamar E C
- Abstract
<bold>Objective: </bold>To document the impact on patient-reported outcomes and health-related quality of life (HRQoL) of treatment with imiquimod cream in patients with actinic keratosis (AK) and superficial basal cell carcinoma (sBCC).<bold>Methods: </bold>This open-label, multicenter study included AK and sBCC patients eligible for treatment with imiquimod 5% cream. HRQoL was measured by the Skindex-17 and the Skin Cancer Index (SCI) and treatment satisfaction by the Treatment Satisfaction Questionnaire for Medication.<bold>Results: </bold>118 AK patients and 84 patients with sBCC were included. Low baseline HRQoL impairment was found on both questionnaires, which remained low after treatment, except for a small dip at the end of the application period.<bold>Conclusion: </bold>Imiquimod 5% cream treatment has no clinically relevant HRQoL impact in AK and sBCC patients according to the Skindex-17 and SCI. The effect of imiquimod treatment on HRQoL may be limited or these questionnaires do not fully capture relevant issues, such as fear of recurrence.
- Publication
Dermatology (10188665), 2015, Vol 231, Issue 1, p56
- ISSN
1018-8665
- Publication type
journal article
- DOI
10.1159/000381420